← Back

Henan Lingrui Pharmaceutical Co Ltd

Henan Lingrui Pharmaceutical Co., Ltd. is a Chinese company that researches, develops, produces, and sells drugs. It operates through the Medical and Healthcare Division and Other segments. Its products come in ten dosage forms, including adhesive plasters, tablets, capsules, granules, and tinctures, for indications such as orthopedic, cardiovascular, cerebrovascular, dermatology, pediatrics, respiratory, nutritional supplements, and anesthesiology. Key products include Tongluoqutong plasters, Peiyuantongnao capsules, Danlutongdu tablets, stomachache free tablets, and Shenqi Hypoglycemic capsules. The company also engages in industrial and real estate investment, technology R&D, ecological agriculture, and high-tech activities. Founded in 1992, it is headquartered in Xinyang, China.

Country
Price · split & dividend adjusted
News & notes moving 600285.CG
600285.CG▲3

Lingrui Pharmaceutical Releases 2026 Interim Report, Net Profit Attributable to Parent at 495 Million Yuan

Lingrui Pharmaceutical released its 2026 interim report on August 12, 2026. The company's total operating revenue was 2.148 billion yuan, net profit attributable to the parent was 495 million yuan, and net cash inflow from operating activities was 723 million yuan. The latest asset-liability ratio was 43.19 percent, up 4.97 percentage points from the previous quarter. Gross margin was 78.90 percent, down 2.43 percentage points from the same period last year. ROE was 15.32 percent, down 0.15 percentage points from the same period last year. Diluted earnings per share was 0.87 yuan, total asset turnover was 0.38 times, and inventory turnover was 1.14 times. The number of shareholders was 41,300, and the top ten shareholders held 31.82 percent of the total share capital.
600285.CG ▲
Jiemian·38dRead more →
600285.CG

Lingrui Group Unpledges 9.75 Million Lingrui Pharmaceutical Shares, Then Re-pledges 5.08 Million

Lingrui Group, a shareholder of Lingrui Pharmaceutical, has released 9.75 million pledged shares, representing 8% of its holdings and 1.72% of the company's total share capital, and subsequently re-pledged 5.08 million shares, accounting for 4.17% of its holdings and 0.9% of the total share capital. As of the announcement date, Lingrui Group has a cumulative pledge of 32.93 million shares, representing 27.03% of its holdings and 5.81% of the company's total share capital. In the first quarter of 2026, Lingrui Pharmaceutical achieved revenue of 1.126 billion yuan and net profit attributable to the parent company of 246 million yuan.
600285.CG
财中社·46dRead more →
© 2026 MarketDXAsset